New inhaled therapy could help preterm infants breathe easier
Disease control
Recruiting now
This Phase 3 trial tests a new inhaled medication called APC-0101 in 520 premature babies born between 26 and 33 weeks who have respiratory distress syndrome. The drug is a surfactant that helps keep tiny air sacs in the lungs open. Some babies receive the active drug through a s…
Phase: PHASE3 • Sponsor: Aerogen Pharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC